Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04521413 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
A Phase 1 study of Advanced Solid Malignancies, sponsored by Treadwell Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 170
- Enrollment target
- 13
- Study locations
NCT04521413: Active Phase 1 study of Advanced Solid Malignancies, sponsored by Treadwell Therapeutics.
NCT04521413 is a Phase 1 study of Advanced Solid Malignancies that is active but no longer recruiting, run by Treadwell Therapeutics. The registered enrollment target is 170 participants, below the 217-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (22% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04521413, a Phase 1 study of Advanced Solid Malignancies, is active but no longer recruiting, sponsored by Treadwell Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 170 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Primary Outcome
The number of subjects who experience an adverse event that was possibly related to study drug.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG CFI-402411
Study Locations (13)
California
- University of California San Diego - La Jolla
- The Angeles Clinic - Los Angeles
Texas
- MD Anderson - Houston
- START - San Antonio - San Antonio
Ontario
- The Ottawa Hospital - Ottawa
- Princess Margaret Cancer Centre - Toronto
Connecticut
- Yale Cancer Center - New Haven
Florida
- Florida Cancer Specialists - Sarasota
Michigan
- START - Mid-West - Grand Rapids
Tennessee
- SCRI - Nashville - Nashville
Virginia
- Virginia Cancer Specialist - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT04521413 still lists
NCT04521413 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 217-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Advanced Solid Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04521413 lists 13 locations in 10 states (California, Texas, Ontario).
Frequently Asked Questions
What is clinical trial NCT04521413 about?
NCT04521413 is a clinical study titled "Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies". The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
What is the current status of trial NCT04521413?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 170 participants. The study started on 2020-08-31. Estimated completion is 2025-12.
What conditions does trial NCT04521413 study?
This clinical trial studies the following conditions: Advanced Solid Malignancies.
What interventions are being tested in trial NCT04521413?
The interventions under investigation include: Pembrolizumab (DRUG), CFI-402411 (DRUG).
Who is sponsoring clinical trial NCT04521413?
This trial is sponsored by Treadwell Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04521413 being conducted?
This trial has 13 study locations across California, Connecticut, Florida, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI